|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | -40.00% |
|
-.--% | -62.50% |
| 26/05 | Ovation Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 01/05 | Ovation Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Revenues | 2L | 1L | 61.93T | 1L | 67.89T | ||||
Total Revenues | 2L | 1L | 61.93T | 1L | 67.89T | ||||
Cost of Goods Sold, Total | 9L | 4.05T | 18.67T | 27.5T | 28.09T | ||||
Gross Profit | -7L | 1L | 43.26T | 85.72T | 39.8T | ||||
Selling General & Admin Expenses, Total | 8L | 8L | 7L | 6L | 6L | ||||
Provision for Bad Debts | - | 52 | 61.29T | - | - | ||||
Stock-Based Compensation (IS) | - | - | 37.7T | - | 68.46T | ||||
R&D Expenses | 83.07T | 65.27T | 8.79T | 12.53T | - | ||||
Depreciation & Amortization - (IS) | 8.02T | 6.73T | 3.24T | 2.12T | - | ||||
Other Operating Expenses, Total | 9L | 9L | 8L | 6L | 6L | ||||
Operating Income | -15.25L | -7L | -8L | -5L | -6L | ||||
Interest Expense, Total | - | -588 | -31.08T | -49.93T | -50.36T | ||||
Interest And Investment Income | 4.72T | 3 | - | - | - | ||||
Net Interest Expenses | 4.72T | -585 | -31.08T | -49.93T | -50.36T | ||||
Currency Exchange Gains (Loss) | -1.93T | -4.17T | 343 | -266 | - | ||||
Other Non Operating Income (Expenses) | -1L | -43.88T | -30.76T | 73.04T | 17.28T | ||||
EBT, Excl. Unusual Items | -16.52L | -8L | -8L | -5L | -6L | ||||
Asset Writedown | -7L | - | - | - | - | ||||
Other Unusual Items | - | - | 15.6T | - | - | ||||
EBT, Incl. Unusual Items | -23.94L | -8L | -8L | -5L | -6L | ||||
Earnings From Continuing Operations | -23.94L | -8L | -8L | -5L | -6L | ||||
Net Income to Company | -23.94L | -8L | -8L | -5L | -6L | ||||
Net Income - (IS) | -23.94L | -8L | -8L | -5L | -6L | ||||
Net Income to Common Incl Extra Items | -23.94L | -8L | -8L | -5L | -6L | ||||
Net Income to Common Excl. Extra Items | -23.94L | -8L | -8L | -5L | -6L | ||||
Per Share Items | |||||||||
Net EPS - Basic | -0.08 | -0.03 | -0.03 | -0.01 | -0.02 | ||||
Basic EPS - Continuing Operations | -0.08 | -0.03 | -0.03 | -0.01 | -0.02 | ||||
Basic Weighted Average Shares Outstanding | 2.94Cr | 2.94Cr | 3.03Cr | 3.5Cr | 3.56Cr | ||||
Net EPS - Diluted | -0.08 | -0.03 | -0.03 | -0.01 | -0.02 | ||||
Diluted EPS - Continuing Operations | -0.08 | -0.03 | -0.03 | -0.01 | -0.02 | ||||
Diluted Weighted Average Shares Outstanding | 2.94Cr | 2.94Cr | 3.03Cr | 3.5Cr | 3.56Cr | ||||
Normalized Basic EPS | -0.04 | -0.02 | -0.02 | -0.01 | -0.01 | ||||
Normalized Diluted EPS | -0.04 | -0.02 | -0.02 | -0.01 | -0.01 | ||||
Supplemental Items | |||||||||
EBITDA | -15.16L | -7L | -8L | -5L | -6L | ||||
EBITA | -15.25L | -7L | -8L | -5L | -6L | ||||
EBIT | -15.25L | -7L | -8L | -5L | -6L | ||||
EBITDAR | -14.92L | -7L | -6L | -4L | - | ||||
Total Revenues (As Reported) | 2L | 1L | 61.93T | 1L | 67.89T | ||||
Normalized Net Income | -10.32L | -5L | -5L | -3L | -4L | ||||
Interest on Long-Term Debt | - | 165 | 13.71T | 24.3T | 19.81T | ||||
Supplemental Operating Expense Items | |||||||||
Advertising Expense | 33.72T | 19.93T | 14.13T | 3.86T | 1.76T | ||||
Selling and Marketing Expenses | 33.72T | 19.93T | 14.13T | 3.86T | 1.76T | ||||
General and Administrative Expenses | 7L | 8L | 7L | 5L | 6L | ||||
Research And Development Expense From Footnotes | 83.07T | 65.27T | 8.79T | 12.53T | - | ||||
Net Rental Expense, Total | 24T | 44.13T | 1L | 97.22T | - | ||||
Imputed Operating Lease Interest Expense | - | - | 3L | 2L | - | ||||
Imputed Operating Lease Depreciation | - | - | -2L | -71.23T | - | ||||
Stock-Based Comp., Other (Total) | - | - | 37.7T | - | 68.46T | ||||
Total Stock-Based Compensation | - | - | 37.7T | - | 68.46T |
- Stock Market
- Stocks
- OVAT Stock
- Financials Ovation Science Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















